Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Guardant Health (GH) to $90 from $110 and keeps an In Line rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health added to Q2 Tactical Ideas List at Wells Fargo
- Guardant Health announces evidence generated from InfinityAI
- Guardant Health, Verana Health announce new partnership
- Insiders Shake Up Guardant, Ovintiv, Redwire, Builders FirstSource, Permian
- Guardant Health price target raised to $130 from $120 at Piper Sandler